Breaking News, Collaborations & Alliances

BMS, Samsung Bio Ink 10-Year Mfg. Pact

Cancer drug to be made in Songdo Incheon

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Bristol-Myers Squibb and Samsung BioLogics have entered into a 10-year agreement under which Samsung will manufacture a commercial antibody cancer drug for BMS at its recently completed plant in Songdo Incheon, South Korea. Financial terms were not disclosed. Technology transfer and trial production will commence in July 2013 and commercial production will immediately begin following regulatory approvals. “We are pleased to announce this strategic manufacturing relationship with Bristol-...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters